Polymorphisms associated with anti‐TNF drugs response in patients with psoriasis and psoriatic arthritis

Abstract

Psoriatic arthritis (PsA) has been classified as an inflammatory musculoskeletal disease with a strong genetic background. Although anti‐TNF drugs are effective for PsA and moderate‐to‐severe psoriasis up to 30‐40% of patients do not respond to them. We evaluated the possible association between 13 single‐nucleotide polymorphisms (SNPs) and anti‐TNF drug response in psoriasis and PsA patients.

This article is protected by copyright. All rights reserved.

http://bit.ly/2VW40nv